Ribosomal protein L7 pseudogene 1 (RPL7P1)

Ribosomal protein L7 pseudogene 1 (RPL7P1) is a processed pseudogene of the functional ribosomal protein L7 (RPL7). It does not produce a functional protein. Unlike its parent gene (RPL7), which encodes a structural component of the ribosome, RPL7P1 is thought to play a role in regulating gene expression through RNA-based mechanisms. Recent research suggests that it may modulate gene networks in the context of diabetes complicated by infections, possibly by acting as a competitive endogenous RNA (ceRNA) sequestering microRNAs such as miR-144-3p, and through interactions with other RNAs and RNA-binding proteins. RPL7P1 has been highlighted as a network hub in regulatory pathways related to cuproptosis (a specialized form of cell death) and may participate in epigenetic modulation of disease states[2][3][13]. There are no drugs directly targeting RPL7P1 as it is not a protein, but some studies have identified drugs that target the RPL7P1 regulative network for management of infections in diabetic patients (specific drugs not named in available abstracts)[2]. Key distinctions: RPL7P1 is a pseudogene, not the functional ribosomal protein or a druggable receptor/enzyme. It acts via regulatory RNA functions, not as a traditional therapeutic target. Summary: RPL7P1 is best classified as a regulatory non-coding pseudogene with emerging relevance to complex disease modulation networks, rather than a conventional therapeutic target or receptor[2][3][13].

Other names

RPL17PRPL7PRPL7_11_628RPL7P1[3][13][19]

Drugs with efficacy may act by modulating networks in which RPL7P1 is a central node, affecting gene regulation via ceRNA and RNA-protein interactions[2]